Who are Conversion schedule - Week 1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Edarbi, Cozaar, Micardis plus 80/12.5, Losartan and Amlodipine, Irbesartan Oral Tablet, olmesartan medoxomil + hydrochlorothiazide, if necessary.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/conversion-schedule-week-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Conversion schedule - Week 1 — Competitive Intelligence Brief

Conversion schedule - Week 1 (Conversion schedule - Week 1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist. Area: Cardiovascular.

marketed Angiotensin II receptor antagonist AT1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Conversion schedule - Week 1 (Conversion schedule - Week 1) — St. Joseph's Hospital and Medical Center, Phoenix. This drug is used to treat hypertension by blocking the action of angiotensin II at its receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Conversion schedule - Week 1 TARGET	Conversion schedule - Week 1	St. Joseph's Hospital and Medical Center, Phoenix	marketed	Angiotensin II receptor antagonist	AT1 receptor
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Cozaar	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
Micardis plus 80/12.5	Micardis plus 80/12.5	Heart Care Foundation	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter
Losartan and Amlodipine	Losartan and Amlodipine	Centro Universitario de Ciencias de la Salud, Mexico	marketed	Angiotensin II receptor antagonist + Calcium channel blocker combination	AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)
Irbesartan Oral Tablet	Irbesartan Oral Tablet	University of Southern Denmark	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
olmesartan medoxomil + hydrochlorothiazide, if necessary	olmesartan medoxomil + hydrochlorothiazide, if necessary	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Edarbi · 9066936 · US
2030-02-04 — Edarbi · 9169238 · US
2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (Angiotensin II receptor antagonist class)

Abbott · 1 drug in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
Ain Shams University · 1 drug in this class
Boryung Pharmaceutical Co., Ltd · 1 drug in this class
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
EMS · 1 drug in this class
Kaohsiung Medical University Chung-Ho Memorial Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
St. Joseph's Hospital and Medical Center, Phoenix · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Conversion schedule - Week 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/conversion-schedule-week-1. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab